3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
Trastuzumab
9
Paclitaxel
8
Capecitabine
8
trastuzumab deruxtecan
7
Fulvestrant
7
pertuzumab
5
eribulin
5
Gemcitabine
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
Doxorubicin
4
Carboplatin
4
Ado-Trastuzumab Emtansine
4
sacituzumab govitecan
3
ribociclib
3
Vinorelbine
3
Epirubicin
3
Docetaxel
3
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
neratinib
2
larotrectinib
2
exemestane
2
capivasertib
2
abemaciclib
2
Letrozole
2
Fluorouracil
2
Anastrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
pegfilgrastim
×
Breast
×
Clear all
NCT03036488
2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3
Completed
1,174 enrolled
1 FDA